HPV Shot Shifts the Odds — Drastically

For the first time on record, an entire generation of young women in England reached adulthood with zero deaths from cervical cancer, and that simple fact might quietly rewrite what we think is possible in cancer prevention.

Story Snapshot

Zero cervical cancer deaths in women aged 20–24 in England from 2020–2024, compared to about 23 expected.
About 200 cervical cancer deaths already prevented in England by human papillomavirus vaccination.
Protection is strongest in girls vaccinated around ages 12–13, with coverage close to 90 percent in the zero-death group.
Global “elimination” still needs high vaccination, strong screening, and fair vaccine access, not just one miracle program.

A five-year window where a deadly cancer simply did not kill

Researchers in England looked at national data on cervical cancer deaths and saw something that has never been recorded before: between 2020 and 2024, not a single woman aged 20 to 24 died from cervical cancer. Based on older, pre-vaccine patterns, about 23 deaths would have been expected in that group over five years. That number did not just drop; it went all the way to zero. For a cancer that once killed hundreds of women a year in England, this is a sharp break with history.

The study, published in The Lancet, credits the national human papillomavirus vaccination program, launched in 2008, for most of this change. Girls in that zero-death age band were offered the vaccine at 12–13 years old, and close to nine in ten took it up. Earlier work in England had already shown an 87 percent drop in cervical cancer cases among women vaccinated at that age. Now, death data catch up with those findings and show the vaccine is not just preventing disease but saving lives in measurable numbers.

How much risk dropped, and for whom

The new analysis does more than celebrate a striking statistic; it estimates how much risk fell and how many deaths were avoided. For women aged 20–24 and 25–29 who had been offered the vaccine as teenagers, the relative risk of dying from cervical cancer was cut by 100 percent compared with historical rates. Women aged 30–34, who had more mixed vaccination patterns, still saw about a 63 percent reduction. Across England, the researchers estimate around 199 cervical cancer deaths were prevented by the end of 2024.

These results match what trials and earlier real-world data had suggested for years: human papillomavirus vaccination slashes the risk of the infections that cause almost all cervical cancers and blocks the slow chain of events that lead from infection to precancer to invasive disease. Studies in several countries have found that girls vaccinated before age 16 can see around a 90 percent drop in cervical cancer incidence. England’s numbers now sit squarely in that same range, but add the final, hardest outcome: mortality.

Why scientists still talk about “observational” evidence and herd protection

Medical journals and public health agencies use careful language for a reason. The English study is observational, not a randomized trial. Researchers followed real-world data in a country where many things changed at once: screening methods improved, public awareness rose, and unvaccinated women gained some protection because the virus spread less widely, a pattern called herd protection. The authors themselves say human papillomavirus vaccination is “unlikely to be 100 percent” effective in a strict biological sense, even if the overall risk appears to drop to near zero for now.

There is also a practical concern: the team suspects a small number of deaths may have been missed in the data for the youngest women. That would mean the 100 percent figure is slightly overstated. This does not undermine the core achievement. The key fact remains that deaths are now so rare in this group that national records, for the first time, show none at all. But it does argue for strong data checks and honest communication, not hype, so public trust stays high.

Where this fits in the bigger fight to eliminate cervical cancer

England’s experience is a sharp local example of a much larger push. The World Health Organization has set a global goal to “eliminate” cervical cancer as a public health problem, defined not as literal zero but as fewer than four cases per 100,000 women. To get there, countries are urged to hit three targets by 2030: vaccinate 90 percent of girls by age 15, screen 70 percent of women twice in midlife, and treat 90 percent of those with disease. Modelling across 78 low-income and lower-middle-income countries finds that vaccination alone barely moves mortality by 2030, but combined with screening and treatment it can cut deaths by one third in that short span and by more than 90 percent over the century.

The statistics now prove the point: HPV vaccination saves lives. In England, cervical cancer deaths among women aged 20–24 have fallen to zero in recent years. Well done to those who introduced HPV vaccination into the national programme. Public health works.#Cancer #vaccines… pic.twitter.com/SocoymwfIp

— Shahram Kordasti (@SKordasti) June 27, 2026

Cervical cancer is still the leading cause of cancer death for women in dozens of countries, especially where vaccine access is scarce and screening is limited. Drug prices, weak health systems, and mistrust slow progress. Some groups worry that high vaccine costs protect company profits more than patients, and they call for open production cost data and lower prices so poorer nations can copy England’s success.

Maintaining trust, tackling hesitancy, and avoiding complacency

The English data show what can happen when a country quietly hits near-ideal coverage in a key age group and backs it with screening programs. Yet even in England, vaccination uptake has dipped from about 90 percent to closer to 75 percent, partly driven by fears that the shot might somehow encourage early sexual activity. Those fears do not match the evidence, but they spread quickly online. Heavy-handed content moderation aimed at “misinformation” can backfire if it looks like officials are hiding debate rather than addressing fair questions.

For parents and policy makers, the lesson is simple and hard at the same time. When most girls receive the human papillomavirus vaccine around age 12 or 13, and when cervical screening remains strong, a once-fatal cancer can be pushed to the edge of extinction in young adults. That is not a theory; it is now written in England’s death records. The next step is making sure this is not a local miracle but the new normal everywhere, by keeping uptake high, defending data honesty, and insisting that life-saving vaccines are worth more than partisan fights or narrow profit goals.